Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation
CD56 expression in acute myeloid leukemia (AML) has been associated with extramedullary leukemia and multidrug resistance, but its clinical and prognostic significance has not been clearly identified. This study examined CD56 expression in 37 adult de novo AML patients with t(8:21). CD56 was express...
Gespeichert in:
| Veröffentlicht in: | American journal of hematology 2007-01, Vol.82 (1), p.1-5 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5 |
|---|---|
| container_issue | 1 |
| container_start_page | 1 |
| container_title | American journal of hematology |
| container_volume | 82 |
| creator | Yang, Deok‐Hwan Lee, Je‐Jung Mun, Yeung‐Chul Shin, Ho‐Jin Kim, Yeo‐Kyeoung Cho, Sang‐Hee Chung, Ik‐Joo Seong, Chu‐Myong Kim, Hyeoung‐Joon |
| description | CD56 expression in acute myeloid leukemia (AML) has been associated with extramedullary leukemia and multidrug resistance, but its clinical and prognostic significance has not been clearly identified. This study examined CD56 expression in 37 adult de novo AML patients with t(8:21). CD56 was expressed in 25 cases (67.6%). Complete remission (CR) rates were similar in both groups (91.7% vs. 88.7%; P = 0.73), but the relapse rates differed considerably (60% vs. 25%; P = 0.02). The median duration of disease‐free survival (DFS) was significantly shorter in the CD56+ (median, 12.2 ± 6.4 months) than in the CD56− group (median, not reached) (P = 0.02). In addition, the median duration of survival differed significantly in the CD56+ group (median, 14.9 ± 4.4 months) compared with the CD56− group (median, not reached) (P = 0.01). Of the fifteen transplanted patients who achieved CR, allogeneic HST was performed from their siblings. The median duration of DFS in the CD56+ patients was significantly shorter than the CD56− patients (median, 24.4 ± 4.5 months vs. median, not reached; P = 0.02). We concluded that CD56 expression correlates to a reduced DFS and survival for AML patients with t(8:21), including those patients who underwent transplantation. Am. J. Hematol., 2006. © 2006 Wiley‐Liss, Inc. |
| doi_str_mv | 10.1002/ajh.20739 |
| format | Article |
| fullrecord | <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_ajh_20739</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>AJH20739</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3889-dd48f2e18bdbc05a1929ed07819a8f435e19310f1fb1f557c6d901efb1bee2d83</originalsourceid><addsrcrecordid>eNp1kM9u1DAQhy0EokvhwAsgX5DoYVvb2WRtbtXyp6BKcIBzNLHHGxfHjmyvyr4Yz4dLVuqJk8eaT_PN_Ah5zdklZ0xcwd14Kdi2UU_IijPVrWXXiqdkxZqO15qpM_Ii5zvGON9I9pyc8U7Jjgu1In--JzROFxg80jnFfYi5OE0t6BITjZbuPrQdxd9zwpxdDNQFOkNxGEqm966MFPShIJ2O6KMz1OPhF04Oll55J98LfkHBFkx0dPuRmpiR6mOBBIMLSKsFvI97DFi9I05Q4hwdPmyRC05Uo_e0JAh59hBKdcfwkjyz4DO-Or3n5Oenjz92N-vbb5-_7K5v17qRUq2N2UgrkMvBDJq1wJVQaNhWcgXSbpoWuWo4s9wO3LbtVndGMY71NyAKI5tzcrHM1SnmnND2c3ITpGPPWf-QfV-z7_9lX9k3CzsfhgnNI3kKuwJvTwBkDd7Wk7TLj5zcCLHlTeWuFu7eeTz-39hff71Z1H8Bg4efHQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Online Library (Open Access Collection)</source><creator>Yang, Deok‐Hwan ; Lee, Je‐Jung ; Mun, Yeung‐Chul ; Shin, Ho‐Jin ; Kim, Yeo‐Kyeoung ; Cho, Sang‐Hee ; Chung, Ik‐Joo ; Seong, Chu‐Myong ; Kim, Hyeoung‐Joon</creator><creatorcontrib>Yang, Deok‐Hwan ; Lee, Je‐Jung ; Mun, Yeung‐Chul ; Shin, Ho‐Jin ; Kim, Yeo‐Kyeoung ; Cho, Sang‐Hee ; Chung, Ik‐Joo ; Seong, Chu‐Myong ; Kim, Hyeoung‐Joon</creatorcontrib><description>CD56 expression in acute myeloid leukemia (AML) has been associated with extramedullary leukemia and multidrug resistance, but its clinical and prognostic significance has not been clearly identified. This study examined CD56 expression in 37 adult de novo AML patients with t(8:21). CD56 was expressed in 25 cases (67.6%). Complete remission (CR) rates were similar in both groups (91.7% vs. 88.7%; P = 0.73), but the relapse rates differed considerably (60% vs. 25%; P = 0.02). The median duration of disease‐free survival (DFS) was significantly shorter in the CD56+ (median, 12.2 ± 6.4 months) than in the CD56− group (median, not reached) (P = 0.02). In addition, the median duration of survival differed significantly in the CD56+ group (median, 14.9 ± 4.4 months) compared with the CD56− group (median, not reached) (P = 0.01). Of the fifteen transplanted patients who achieved CR, allogeneic HST was performed from their siblings. The median duration of DFS in the CD56+ patients was significantly shorter than the CD56− patients (median, 24.4 ± 4.5 months vs. median, not reached; P = 0.02). We concluded that CD56 expression correlates to a reduced DFS and survival for AML patients with t(8:21), including those patients who underwent transplantation. Am. J. Hematol., 2006. © 2006 Wiley‐Liss, Inc.</description><identifier>ISSN: 0361-8609</identifier><identifier>EISSN: 1096-8652</identifier><identifier>DOI: 10.1002/ajh.20739</identifier><identifier>PMID: 16986129</identifier><identifier>CODEN: AJHEDD</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adolescent ; Adult ; allogeneic stem cell transplantation ; AML with t(8;21) ; Antimetabolites, Antineoplastic - administration & dosage ; Biological and medical sciences ; Biomarkers, Tumor - biosynthesis ; Biomarkers, Tumor - genetics ; CD56 Antigen - biosynthesis ; CD56 Antigen - genetics ; CD56 expression ; Chromosomes, Human, Pair 21 - genetics ; Chromosomes, Human, Pair 8 - genetics ; Cytarabine - administration & dosage ; Disease-Free Survival ; Female ; Gene Expression Regulation, Leukemic ; Hematologic and hematopoietic diseases ; Hematopoietic Stem Cell Transplantation - mortality ; Humans ; Leukemia, Myeloid, Acute - genetics ; Leukemia, Myeloid, Acute - metabolism ; Leukemia, Myeloid, Acute - mortality ; Leukemia, Myeloid, Acute - therapy ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Medical sciences ; Middle Aged ; Predictive Value of Tests ; prognostic significance ; Recurrence ; Remission Induction ; Retrospective Studies ; survival ; Survival Rate ; Translocation, Genetic ; Transplantation, Homologous</subject><ispartof>American journal of hematology, 2007-01, Vol.82 (1), p.1-5</ispartof><rights>Copyright © 2006 Wiley‐Liss, Inc.</rights><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3889-dd48f2e18bdbc05a1929ed07819a8f435e19310f1fb1f557c6d901efb1bee2d83</citedby><cites>FETCH-LOGICAL-c3889-dd48f2e18bdbc05a1929ed07819a8f435e19310f1fb1f557c6d901efb1bee2d83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fajh.20739$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fajh.20739$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,782,786,1419,1435,4026,27930,27931,27932,45581,45582,46416,46840</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18422713$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16986129$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, Deok‐Hwan</creatorcontrib><creatorcontrib>Lee, Je‐Jung</creatorcontrib><creatorcontrib>Mun, Yeung‐Chul</creatorcontrib><creatorcontrib>Shin, Ho‐Jin</creatorcontrib><creatorcontrib>Kim, Yeo‐Kyeoung</creatorcontrib><creatorcontrib>Cho, Sang‐Hee</creatorcontrib><creatorcontrib>Chung, Ik‐Joo</creatorcontrib><creatorcontrib>Seong, Chu‐Myong</creatorcontrib><creatorcontrib>Kim, Hyeoung‐Joon</creatorcontrib><title>Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation</title><title>American journal of hematology</title><addtitle>Am J Hematol</addtitle><description>CD56 expression in acute myeloid leukemia (AML) has been associated with extramedullary leukemia and multidrug resistance, but its clinical and prognostic significance has not been clearly identified. This study examined CD56 expression in 37 adult de novo AML patients with t(8:21). CD56 was expressed in 25 cases (67.6%). Complete remission (CR) rates were similar in both groups (91.7% vs. 88.7%; P = 0.73), but the relapse rates differed considerably (60% vs. 25%; P = 0.02). The median duration of disease‐free survival (DFS) was significantly shorter in the CD56+ (median, 12.2 ± 6.4 months) than in the CD56− group (median, not reached) (P = 0.02). In addition, the median duration of survival differed significantly in the CD56+ group (median, 14.9 ± 4.4 months) compared with the CD56− group (median, not reached) (P = 0.01). Of the fifteen transplanted patients who achieved CR, allogeneic HST was performed from their siblings. The median duration of DFS in the CD56+ patients was significantly shorter than the CD56− patients (median, 24.4 ± 4.5 months vs. median, not reached; P = 0.02). We concluded that CD56 expression correlates to a reduced DFS and survival for AML patients with t(8:21), including those patients who underwent transplantation. Am. J. Hematol., 2006. © 2006 Wiley‐Liss, Inc.</description><subject>Adolescent</subject><subject>Adult</subject><subject>allogeneic stem cell transplantation</subject><subject>AML with t(8;21)</subject><subject>Antimetabolites, Antineoplastic - administration & dosage</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - biosynthesis</subject><subject>Biomarkers, Tumor - genetics</subject><subject>CD56 Antigen - biosynthesis</subject><subject>CD56 Antigen - genetics</subject><subject>CD56 expression</subject><subject>Chromosomes, Human, Pair 21 - genetics</subject><subject>Chromosomes, Human, Pair 8 - genetics</subject><subject>Cytarabine - administration & dosage</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Gene Expression Regulation, Leukemic</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematopoietic Stem Cell Transplantation - mortality</subject><subject>Humans</subject><subject>Leukemia, Myeloid, Acute - genetics</subject><subject>Leukemia, Myeloid, Acute - metabolism</subject><subject>Leukemia, Myeloid, Acute - mortality</subject><subject>Leukemia, Myeloid, Acute - therapy</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Predictive Value of Tests</subject><subject>prognostic significance</subject><subject>Recurrence</subject><subject>Remission Induction</subject><subject>Retrospective Studies</subject><subject>survival</subject><subject>Survival Rate</subject><subject>Translocation, Genetic</subject><subject>Transplantation, Homologous</subject><issn>0361-8609</issn><issn>1096-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM9u1DAQhy0EokvhwAsgX5DoYVvb2WRtbtXyp6BKcIBzNLHHGxfHjmyvyr4Yz4dLVuqJk8eaT_PN_Ah5zdklZ0xcwd14Kdi2UU_IijPVrWXXiqdkxZqO15qpM_Ii5zvGON9I9pyc8U7Jjgu1In--JzROFxg80jnFfYi5OE0t6BITjZbuPrQdxd9zwpxdDNQFOkNxGEqm966MFPShIJ2O6KMz1OPhF04Oll55J98LfkHBFkx0dPuRmpiR6mOBBIMLSKsFvI97DFi9I05Q4hwdPmyRC05Uo_e0JAh59hBKdcfwkjyz4DO-Or3n5Oenjz92N-vbb5-_7K5v17qRUq2N2UgrkMvBDJq1wJVQaNhWcgXSbpoWuWo4s9wO3LbtVndGMY71NyAKI5tzcrHM1SnmnND2c3ITpGPPWf-QfV-z7_9lX9k3CzsfhgnNI3kKuwJvTwBkDd7Wk7TLj5zcCLHlTeWuFu7eeTz-39hff71Z1H8Bg4efHQ</recordid><startdate>200701</startdate><enddate>200701</enddate><creator>Yang, Deok‐Hwan</creator><creator>Lee, Je‐Jung</creator><creator>Mun, Yeung‐Chul</creator><creator>Shin, Ho‐Jin</creator><creator>Kim, Yeo‐Kyeoung</creator><creator>Cho, Sang‐Hee</creator><creator>Chung, Ik‐Joo</creator><creator>Seong, Chu‐Myong</creator><creator>Kim, Hyeoung‐Joon</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>200701</creationdate><title>Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation</title><author>Yang, Deok‐Hwan ; Lee, Je‐Jung ; Mun, Yeung‐Chul ; Shin, Ho‐Jin ; Kim, Yeo‐Kyeoung ; Cho, Sang‐Hee ; Chung, Ik‐Joo ; Seong, Chu‐Myong ; Kim, Hyeoung‐Joon</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3889-dd48f2e18bdbc05a1929ed07819a8f435e19310f1fb1f557c6d901efb1bee2d83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>allogeneic stem cell transplantation</topic><topic>AML with t(8;21)</topic><topic>Antimetabolites, Antineoplastic - administration & dosage</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - biosynthesis</topic><topic>Biomarkers, Tumor - genetics</topic><topic>CD56 Antigen - biosynthesis</topic><topic>CD56 Antigen - genetics</topic><topic>CD56 expression</topic><topic>Chromosomes, Human, Pair 21 - genetics</topic><topic>Chromosomes, Human, Pair 8 - genetics</topic><topic>Cytarabine - administration & dosage</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Gene Expression Regulation, Leukemic</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematopoietic Stem Cell Transplantation - mortality</topic><topic>Humans</topic><topic>Leukemia, Myeloid, Acute - genetics</topic><topic>Leukemia, Myeloid, Acute - metabolism</topic><topic>Leukemia, Myeloid, Acute - mortality</topic><topic>Leukemia, Myeloid, Acute - therapy</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Predictive Value of Tests</topic><topic>prognostic significance</topic><topic>Recurrence</topic><topic>Remission Induction</topic><topic>Retrospective Studies</topic><topic>survival</topic><topic>Survival Rate</topic><topic>Translocation, Genetic</topic><topic>Transplantation, Homologous</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Deok‐Hwan</creatorcontrib><creatorcontrib>Lee, Je‐Jung</creatorcontrib><creatorcontrib>Mun, Yeung‐Chul</creatorcontrib><creatorcontrib>Shin, Ho‐Jin</creatorcontrib><creatorcontrib>Kim, Yeo‐Kyeoung</creatorcontrib><creatorcontrib>Cho, Sang‐Hee</creatorcontrib><creatorcontrib>Chung, Ik‐Joo</creatorcontrib><creatorcontrib>Seong, Chu‐Myong</creatorcontrib><creatorcontrib>Kim, Hyeoung‐Joon</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>American journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Deok‐Hwan</au><au>Lee, Je‐Jung</au><au>Mun, Yeung‐Chul</au><au>Shin, Ho‐Jin</au><au>Kim, Yeo‐Kyeoung</au><au>Cho, Sang‐Hee</au><au>Chung, Ik‐Joo</au><au>Seong, Chu‐Myong</au><au>Kim, Hyeoung‐Joon</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation</atitle><jtitle>American journal of hematology</jtitle><addtitle>Am J Hematol</addtitle><date>2007-01</date><risdate>2007</risdate><volume>82</volume><issue>1</issue><spage>1</spage><epage>5</epage><pages>1-5</pages><issn>0361-8609</issn><eissn>1096-8652</eissn><coden>AJHEDD</coden><abstract>CD56 expression in acute myeloid leukemia (AML) has been associated with extramedullary leukemia and multidrug resistance, but its clinical and prognostic significance has not been clearly identified. This study examined CD56 expression in 37 adult de novo AML patients with t(8:21). CD56 was expressed in 25 cases (67.6%). Complete remission (CR) rates were similar in both groups (91.7% vs. 88.7%; P = 0.73), but the relapse rates differed considerably (60% vs. 25%; P = 0.02). The median duration of disease‐free survival (DFS) was significantly shorter in the CD56+ (median, 12.2 ± 6.4 months) than in the CD56− group (median, not reached) (P = 0.02). In addition, the median duration of survival differed significantly in the CD56+ group (median, 14.9 ± 4.4 months) compared with the CD56− group (median, not reached) (P = 0.01). Of the fifteen transplanted patients who achieved CR, allogeneic HST was performed from their siblings. The median duration of DFS in the CD56+ patients was significantly shorter than the CD56− patients (median, 24.4 ± 4.5 months vs. median, not reached; P = 0.02). We concluded that CD56 expression correlates to a reduced DFS and survival for AML patients with t(8:21), including those patients who underwent transplantation. Am. J. Hematol., 2006. © 2006 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>16986129</pmid><doi>10.1002/ajh.20739</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0361-8609 |
| ispartof | American journal of hematology, 2007-01, Vol.82 (1), p.1-5 |
| issn | 0361-8609 1096-8652 |
| language | eng |
| recordid | cdi_crossref_primary_10_1002_ajh_20739 |
| source | Wiley Online Library - AutoHoldings Journals; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Online Library (Open Access Collection) |
| subjects | Adolescent Adult allogeneic stem cell transplantation AML with t(8 21) Antimetabolites, Antineoplastic - administration & dosage Biological and medical sciences Biomarkers, Tumor - biosynthesis Biomarkers, Tumor - genetics CD56 Antigen - biosynthesis CD56 Antigen - genetics CD56 expression Chromosomes, Human, Pair 21 - genetics Chromosomes, Human, Pair 8 - genetics Cytarabine - administration & dosage Disease-Free Survival Female Gene Expression Regulation, Leukemic Hematologic and hematopoietic diseases Hematopoietic Stem Cell Transplantation - mortality Humans Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - metabolism Leukemia, Myeloid, Acute - mortality Leukemia, Myeloid, Acute - therapy Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Middle Aged Predictive Value of Tests prognostic significance Recurrence Remission Induction Retrospective Studies survival Survival Rate Translocation, Genetic Transplantation, Homologous |
| title | Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T12%3A24%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predictable%20prognostic%20factor%20of%20CD56%20expression%20in%20patients%20with%20acute%20myeloid%20leukemia%20with%20t(8:21)%20after%20high%20dose%20cytarabine%20or%20allogeneic%20hematopoietic%20stem%20cell%20transplantation&rft.jtitle=American%20journal%20of%20hematology&rft.au=Yang,%20Deok%E2%80%90Hwan&rft.date=2007-01&rft.volume=82&rft.issue=1&rft.spage=1&rft.epage=5&rft.pages=1-5&rft.issn=0361-8609&rft.eissn=1096-8652&rft.coden=AJHEDD&rft_id=info:doi/10.1002/ajh.20739&rft_dat=%3Cwiley_cross%3EAJH20739%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/16986129&rfr_iscdi=true |